Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Translating neoadjuvant therapy into survival benefits: one size does not fit all.

Nature reviews. Clinical oncology - 1 Sept 2016

De Mattos-Arruda Leticia, Shen Ronglai, Reis-Filho Jorge S, Cortés Javier

Abstract excerpt

Neoadjuvant therapy has been established as an effective therapeutic approach for patients with locally advanced breast cancer. Similar outcomes between neoadjuvant and adjuvant chemotherapy have been demonstrated in several trials. Nevertheless, neoadjuvant therapy has some advantages over adjuvant therapy, including tumour downstaging, in vivo assessment of therapeutic efficacy, reduced treatment durations, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Genetic Heterogeneity

Share to Neoadjuvant Therapy

Share to Patient Selection

Share to Receptor, ErbB-2

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 27000962
DOI: 10.1038/nrclinonc.2016.35
PMCID: PMC5118200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Translating neoadjuvant therapy into survival benefits: one size does not fit all.PMID 27000962Read ↗

Neoadjuvant chemotherapy and targeted therapies: a promising strategy.Semantic proximity Read ↗

Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?Semantic proximity Read ↗

Facts and controversies in the use of trastuzumab in the adjuvant setting.Semantic proximity Read ↗

Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsSemantic proximity Read ↗

Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes.Semantic proximity Read ↗

The relationship between hormone receptor status, tumor size and clinical stage and the efficacy of neoadjuvant chemotherapy for locally advanced breast cancer, predictors of survival, and the establishment of Cox-Based risk prediction model and nomogramSemantic proximity Read ↗

Novel Prognostic Stratification and Therapeutic Implications in T1N0M0 Breast Cancer: Insights from a Multi-Center Chinese CohortSemantic proximity Read ↗

Predictive factors for response to neoadjuvant therapy in breast cancer.Semantic proximity Read ↗

The new millennium for adjuvant therapy in breast cancer.Semantic proximity Read ↗

Effect of Neoadjuvant Chemotherapy on Breast Conservative Surgery of Breast CancerSemantic proximity Read ↗

Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer.Semantic proximity Read ↗

Long-term Results of the Expanded Application of the ACOSOG Z0011 Trial for Patients with Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.